Roxane Laboratories, Inc.; Withdrawal of Approval of a New Drug Application for ROXICODONE (Oxycodone Hydrochloride) Sustained-Release Tablets, 10 Milligrams and 30 Milligrams, 56606-56607 [2017-25771]
Download as PDF
56606
Federal Register / Vol. 82, No. 228 / Wednesday, November 29, 2017 / Notices
September 18, 2015, or access the
information at: https://www.gpo.gov/
fdsys/pkg/FR-2015-09-18/pdf/201523389.pdf.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Dockets Management
Staff, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT:
Beverly Friedman, Office of Regulatory
Policy, Food and Drug Administration,
10903 New Hampshire Ave., Bldg. 51,
Rm. 6250, Silver Spring, MD 20993,
301–796–3600.
SUPPLEMENTARY INFORMATION:
pmangrum on DSK3GDR082PROD with NOTICES1
I. Background
The Drug Price Competition and
Patent Term Restoration Act of 1984
(Pub. L. 98–417) and the Generic
Animal Drug and Patent Term
Restoration Act (Pub. L. 100–670)
generally provide that a patent may be
extended for a period of up to 5 years
so long as the patented item (human
drug product, animal drug product,
medical device, food additive, or color
additive) was subject to regulatory
review by FDA before the item was
marketed. Under these acts, a product’s
regulatory review period forms the basis
for determining the amount of extension
an applicant may receive.
A regulatory review period consists of
two periods of time: A testing phase and
an approval phase. For human drug
products, the testing phase begins when
the exemption to permit the clinical
investigations of the drug becomes
effective and runs until the approval
phase begins. The approval phase starts
with the initial submission of an
application to market the human drug
product and continues until FDA grants
permission to market the drug product.
Although only a portion of a regulatory
review period may count toward the
actual amount of extension that the
Director of USPTO may award (for
example, half the testing phase must be
subtracted as well as any time that may
have occurred before the patent was
issued), FDA’s determination of the
length of a regulatory review period for
a human drug product will include all
of the testing phase and approval phase
as specified in 35 U.S.C. 156(g)(1)(B).
FDA has approved for marketing the
human drug product XURIDEN (uridine
triacetate). XURIDEN is indicated for the
treatment of hereditary orotic aciduria.
VerDate Sep<11>2014
15:19 Nov 28, 2017
Jkt 241001
Subsequent to this approval, the USPTO
received a patent term restoration
application for XURIDEN (U.S. Patent
No. 6,258,795) from Wellstat
Therapeutics Corp., and the USPTO
requested FDA’s assistance in
determining this patent’s eligibility for
patent term restoration. In a letter dated
August 25, 2016, FDA advised the
USPTO that this human drug product
had undergone a regulatory review
period and that the approval of
XURIDEN represented the first
permitted commercial marketing or use
of the product. Thereafter, the USPTO
requested that FDA determine the
product’s regulatory review period.
II. Determination of Regulatory Review
Period
FDA has determined that the
applicable regulatory review period for
XURIDEN is 8,494 days. Of this time,
8,254 days occurred during the testing
phase of the regulatory review period,
while 240 days occurred during the
approval phase. These periods of time
were derived from the following dates:
1. The date an exemption under
section 505(i) of the Federal Food, Drug,
and Cosmetic Act (the FD&C Act) (21
U.S.C. 355(i)) became effective: June 4,
1992. The applicant claims May 4, 1992,
as the date the investigational new drug
application (IND) became effective.
However, FDA records indicate that the
IND effective date was June 4, 1992,
which was 30 days after FDA receipt of
the IND.
2. The date the application was
initially submitted with respect to the
human drug product under section
505(b) of the FD&C Act: January 8, 2015.
FDA has verified the applicant’s claim
that the new drug application (NDA) for
XURIDEN (NDA 208169) was initially
submitted on January 8, 2015.
3. The date the application was
approved: September 4, 2015. FDA has
verified the applicant’s claim that NDA
208169 was approved on September 4,
2015.
This determination of the regulatory
review period establishes the maximum
potential length of a patent extension.
However, the USPTO applies several
statutory limitations in its calculations
of the actual period for patent extension.
In its application for patent extension,
this applicant seeks 5 years of patent
term extension.
III. Petitions
Anyone with knowledge that any of
the dates as published are incorrect may
submit either electronic or written
comments and, under 21 CFR 60.24, ask
for a redetermination (see DATES).
Furthermore, as specified in § 60.30 (21
PO 00000
Frm 00027
Fmt 4703
Sfmt 4703
CFR 60.30), any interested person may
petition FDA for a determination
regarding whether the applicant for
extension acted with due diligence
during the regulatory review period. To
meet its burden, the petition must
comply with all the requirements of 21
CFR 60.30, including but not limited to:
Must be timely (see DATES), must be
filed in accordance with 21 CFR 10.20,
must contain sufficient facts to merit an
FDA investigation, and must certify that
a true and complete copy of the petition
has been served upon the patent
applicant. (See H. Rept. 857, part 1, 98th
Cong., 2d sess., pp. 41–42, 1984.)
Petitions should be in the format
specified in 21 CFR 10.30.
Submit petitions electronically to
https://www.regulations.gov at Docket
No. FDA–2013–S–0610. Submit written
petitions (two copies are required) to the
Dockets Management Staff (HFA–305),
Food and Drug Administration, 5630
Fishers Lane, Rm. 1061, Rockville, MD
20852.
Dated: November 24, 2017.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2017–25770 Filed 11–28–17; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2017–N–6373]
Roxane Laboratories, Inc.; Withdrawal
of Approval of a New Drug Application
for ROXICODONE (Oxycodone
Hydrochloride) Sustained-Release
Tablets, 10 Milligrams and 30
Milligrams
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA or Agency) is
withdrawing approval of new drug
application (NDA) 020932 for
ROXICODONE (oxycodone
hydrochloride (HCl)) Sustained-Release
Tablets, 10 milligrams (mg) and 30 mg,
held by Roxane Laboratories, Inc.
(Roxane). Roxane requested withdrawal
of this application and waived its
opportunity for a hearing.
DATES: The approval is withdrawn as of
November 29, 2017.
FOR FURTHER INFORMATION CONTACT:
Kristiana Brugger, Office of Regulatory
Policy, Center for Drug Evaluation and
Research, Food and Drug
Administration, 10903 New Hampshire
SUMMARY:
E:\FR\FM\29NON1.SGM
29NON1
Federal Register / Vol. 82, No. 228 / Wednesday, November 29, 2017 / Notices
Ave., Bldg. 51, Rm. 6262, Silver Spring,
MD 20993, 301–796–3601.
NDA
020932 for ROXICODONE SR
(oxycodone HCl) Sustained-Release
Tablets, 10 mg and 30 mg, was received
on December 29, 1997, and approved on
October 26, 1998, as safe and effective
‘‘for the management of moderate to
severe pain where use of an opioid
analgesic is appropriate for more than a
few days’’ (see approval letter, available
at https://www.accessdata.fda.gov/
drugsatfda_docs/appletter/1998/
20932ltr.pdf). (FDA has verified the
Web site addresses as of the date this
document publishes in the Federal
Register, but Web sites are subject to
change over time.) FDA later
determined, however, that this
application had serious deficiencies.
Accordingly, on February 3, 2000, FDA
granted Roxane’s request for a stay of
the effective date of the approval of
NDA 020932 until such time as: (1)
Roxane submits additional data; (2) FDA
has reviewed those data; and (3) FDA
has determined that the submitted data
support a finding of safety and
effectiveness without reliance on
investigations to which Roxane does not
have a right of reference.1 Roxane has
not submitted any additional
information to support approval of NDA
020932, nor has it submitted any annual
reports for this NDA since 2002. The
product has never been marketed.2
Roxane requested that FDA withdraw
approval of NDA 020932 for
ROXICODONE (oxycodone HCl)
Sustained Release Tablets, and waived
the opportunity for a hearing concerning
this action.
For the reasons discussed above,
approval of NDA 020932, and all
amendments and supplements thereto,
is withdrawn. Distribution of
ROXICODONE (oxycodone HCl)
Sustained-Release Tablets, 10 mg and 30
mg, in interstate commerce without an
approved application is illegal and
subject to regulatory action (see sections
505(a) and 301(d) of the FD&C Act (21
U.S.C. 355(a) and 331(d)).
pmangrum on DSK3GDR082PROD with NOTICES1
SUPPLEMENTARY INFORMATION:
1 February 3, 2000 FDA Response to Citizen
Petition and Petition for Stay of Action, Docket
FDA–1999–P–2921, available at https://
www.regulations.gov/document?D=FDA-1999-P2921-0014.
2 Reflecting their non-marketed status,
ROXICODONE (oxycodone HCl) Sustained-Release
Tablets, 10 mg and 30 mg, are on the ‘‘Discontinued
Drug Products’’ list in the Orange Book, where the
drug is listed as ‘‘Roxicodone’’ and described as
‘‘extended release’’ (see https://
www.accessdata.fda.gov/scripts/cder/ob/results_
product.cfm?Appl_Type=N&Appl_No=020932).
VerDate Sep<11>2014
15:19 Nov 28, 2017
Jkt 241001
Dated: November 24, 2017.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2017–25771 Filed 11–28–17; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2017–D–5570]
Select Updates for Recommendations
for Clinical Laboratory Improvement
Amendments of 1988 Waiver
Applications for Manufacturers of In
Vitro Diagnostic Devices; Draft
Guidance for Industry and Food and
Drug Administration Staff; Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of availability.
The Food and Drug
Administration (FDA or Agency) is
announcing the availability of the draft
guidance entitled ‘‘Select Updates for
Recommendations for Clinical
Laboratory Improvement Amendments
of 1988 (CLIA) Waiver Applications for
Manufacturers of In Vitro Diagnostic
Devices.’’ FDA has developed this draft
guidance to implement a section of the
21st Century Cures Act (Cures Act) that
requires FDA to revise ‘‘V.
Demonstrating Insignificant Risk of an
Erroneous Result—Accuracy’’ of the
guidance ‘‘Recommendations for
Clinical Laboratory Improvement
Amendments of 1988 (CLIA) Waiver
Applications for Manufacturers of In
Vitro Diagnostic Devices’’ (‘‘2008 CLIA
Waiver Guidance’’) that was issued on
January 30, 2008. This draft guidance
updates FDA’s thinking regarding the
appropriate use of comparable
performance between a waived user and
a moderately complex laboratory user to
demonstrate accuracy. This draft
guidance is not final nor is it in effect
at this time.
DATES: Submit either electronic or
written comments on the draft guidance
by January 29, 2018 to ensure that the
Agency considers your comment on this
draft guidance before it begins work on
the final version of the guidance.
ADDRESSES: You may submit comments
on any guidance at any time as follows:
SUMMARY:
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
PO 00000
Frm 00028
Fmt 4703
Sfmt 4703
56607
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2017–D–5570 for ‘‘Recommendations
for Clinical Laboratory Improvement
Amendments of 1988 (CLIA) Waiver
Applications for Manufacturers of In
Vitro Diagnostic Devices.’’ Received
comments will be placed in the docket
and, except for those submitted as
‘‘Confidential Submissions,’’ publicly
viewable at https://www.regulations.gov
or at the Dockets Management Staff
between 9 a.m. and 4 p.m., Monday
through Friday.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
E:\FR\FM\29NON1.SGM
29NON1
Agencies
[Federal Register Volume 82, Number 228 (Wednesday, November 29, 2017)]
[Notices]
[Pages 56606-56607]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-25771]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2017-N-6373]
Roxane Laboratories, Inc.; Withdrawal of Approval of a New Drug
Application for ROXICODONE (Oxycodone Hydrochloride) Sustained-Release
Tablets, 10 Milligrams and 30 Milligrams
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or Agency) is
withdrawing approval of new drug application (NDA) 020932 for
ROXICODONE (oxycodone hydrochloride (HCl)) Sustained-Release Tablets,
10 milligrams (mg) and 30 mg, held by Roxane Laboratories, Inc.
(Roxane). Roxane requested withdrawal of this application and waived
its opportunity for a hearing.
DATES: The approval is withdrawn as of November 29, 2017.
FOR FURTHER INFORMATION CONTACT: Kristiana Brugger, Office of
Regulatory Policy, Center for Drug Evaluation and Research, Food and
Drug Administration, 10903 New Hampshire
[[Page 56607]]
Ave., Bldg. 51, Rm. 6262, Silver Spring, MD 20993, 301-796-3601.
SUPPLEMENTARY INFORMATION: NDA 020932 for ROXICODONE SR (oxycodone HCl)
Sustained-Release Tablets, 10 mg and 30 mg, was received on December
29, 1997, and approved on October 26, 1998, as safe and effective ``for
the management of moderate to severe pain where use of an opioid
analgesic is appropriate for more than a few days'' (see approval
letter, available at https://www.accessdata.fda.gov/drugsatfda_docs/appletter/1998/20932ltr.pdf). (FDA has verified the Web site addresses
as of the date this document publishes in the Federal Register, but Web
sites are subject to change over time.) FDA later determined, however,
that this application had serious deficiencies. Accordingly, on
February 3, 2000, FDA granted Roxane's request for a stay of the
effective date of the approval of NDA 020932 until such time as: (1)
Roxane submits additional data; (2) FDA has reviewed those data; and
(3) FDA has determined that the submitted data support a finding of
safety and effectiveness without reliance on investigations to which
Roxane does not have a right of reference.\1\ Roxane has not submitted
any additional information to support approval of NDA 020932, nor has
it submitted any annual reports for this NDA since 2002. The product
has never been marketed.\2\ Roxane requested that FDA withdraw approval
of NDA 020932 for ROXICODONE (oxycodone HCl) Sustained Release Tablets,
and waived the opportunity for a hearing concerning this action.
---------------------------------------------------------------------------
\1\ February 3, 2000 FDA Response to Citizen Petition and
Petition for Stay of Action, Docket FDA-1999-P-2921, available at
https://www.regulations.gov/document?D=FDA-1999-P-2921-0014.
\2\ Reflecting their non-marketed status, ROXICODONE (oxycodone
HCl) Sustained-Release Tablets, 10 mg and 30 mg, are on the
``Discontinued Drug Products'' list in the Orange Book, where the
drug is listed as ``Roxicodone'' and described as ``extended
release'' (see https://www.accessdata.fda.gov/scripts/cder/ob/results_product.cfm?Appl_Type=N&Appl_No=020932).
---------------------------------------------------------------------------
For the reasons discussed above, approval of NDA 020932, and all
amendments and supplements thereto, is withdrawn. Distribution of
ROXICODONE (oxycodone HCl) Sustained-Release Tablets, 10 mg and 30 mg,
in interstate commerce without an approved application is illegal and
subject to regulatory action (see sections 505(a) and 301(d) of the
FD&C Act (21 U.S.C. 355(a) and 331(d)).
Dated: November 24, 2017.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2017-25771 Filed 11-28-17; 8:45 am]
BILLING CODE 4164-01-P